- Investing.com
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Strategic Expansion | Delve into Thermo Fisher's acquisition of Solventum, a move poised to enhance its market position in bioprocessing and open doors to new industrial sectors |
Financial Resilience | Explore Thermo Fisher's robust financial performance, with FY2025 organic growth projections of 3-4% and EPS estimates ranging from $23.10 to $23.50 |
Market Dynamics | Uncover the complexities of Thermo Fisher's market landscape, including the impact of Chinese economic uncertainties and the momentum in bioproduction sectors |
Future Trajectory | Analyst price targets for Thermo Fisher range from $600 to $718, reflecting varied perspectives on the company's growth potential and market positioning |
Metrics to compare | TMO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTMOPeersSector | |
---|---|---|---|---|
P/E Ratio | 22.7x | 3.5x | −0.4x | |
PEG Ratio | 2.42 | −0.05 | 0.00 | |
Price/Book | 3.0x | 2.2x | 2.6x | |
Price / LTM Sales | 3.5x | 3.5x | 3.0x | |
Upside (Analyst Target) | 43.3% | 19.9% | 52.3% | |
Fair Value Upside | Unlock | 28.8% | 9.4% | Unlock |